Find Information About:

Drugs & Supplements

Get information and reviews on prescription drugs, over-the-counter medications, vitamins, and supplements. Search by name or medical condition.

Pill Identifier

Pill Identifier

Having trouble identifying your pills?

Enter the shape, color, or imprint of your prescription or OTC drug. Our pill identification tool will display pictures that you can compare to your pill.

Get Started

My Medicine

Save your medicine, check interactions, sign up for FDA alerts, create family profiles and more.

Get Started

WebMD Health Experts and Community

Talk to health experts and other people like you in WebMD's Communities. It's a safe forum where you can create or participate in support groups and discussions about health topics that interest you.

  • Second Opinion

    Second Opinion

    Read expert perspectives on popular health topics.

  • Community


    Connect with people like you, and get expert guidance on living a healthy life.

Got a health question? Get answers provided by leading organizations, doctors, and experts.

Get Answers

Sign up to receive WebMD's award-winning content delivered to your inbox.

Sign Up

Font Size

PSA Test Cuts Prostate Cancer Deaths -- at a Cost

European PSA Study: Screen 936 Men, Save 1 Cancer Death

European PSA Study vs. U.S. PSA Study

The European findings are in contrast to those from the U.S. Prostate, Lung, Colorectal, and Ovarian (PLCO) study. Miller says the U.S. study "shows absolutely no indication of a benefit" even after 13 years of routine PSA screening.

Miller, one of the PLCO investigators, is critical of the European study. In an editorial accompanying the Schroder report, he suggests that PSA-screened men were more likely to be treated for prostate cancer at academic centers, where they got more state-of-the-art treatment.

And even though the screened men were less likely to die of prostate cancer, death from any cause was just as likely in screened as in unscreened men.

Schroder says the PLCO study has its own flaws -- not least of which is that about half the men in the group that was supposed to be unscreened actually had a PSA test before the study began. This, he says, means that many men with hidden, aggressive cancers were never enrolled in that group.

Indeed, in the European study, three-fourths of the screened men who died of prostate cancer had their disease detected on first screening.

Both Schroder and Miller agree that while they complement each other in some ways, the two large PSA studies have many differences. These include:

  • European men were screened only once every four years (every two years in Sweden); U.S. men were screened every year.
  • In Europe, screened men got prostate biopsies when their PSA level was 3 ng/mL. In the U.S., the PSA cutoff was 4 ng/mL.
  • In the European study, 13% of screening tests were false positives (no cancer detected on biopsy). The false-positive rate in the U.S. study was 7%.
  • The European PSA study enrolled about twice as many men as the U.S. study.
  • Overdiagnosis rates were about 50% in the European trial, but 17% to 30% in the U.S. trial.

The PSA Test: Advice to Men

Despite their very different takes on the two PSA studies, Schroder and Miller are in remarkable agreement about the lessons men should take from them.

Today on WebMD

man with doctor
Symptoms, risks, treatments
man coughing
Men shouldn’t ignore
prostate cancer cells
What does this diagnosis mean?
doctor and male patient
Is it worth it?
cancer fighting foods
15 Cancer Symptoms Men Ignore
Prostate Enlarged
Picture Of The Prostate
Prostate Cancer Quiz
screening tests for men
Prostate Cancer Symptoms
Vitamin D